Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 2/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31545899 | 0.87 | MEN1 (0.67) | MEN1MAPTKMT2AALOX5IDO1 | |
| SCHEMBL23903545 | 0.81 | MEN1 (0.50) | MEN1MAPTKMT2AALOX5ESR1 | |
| SCHEMBL22214947 | 0.81 | MAPT (0.50) | MEN1MAPTKMT2AALOX5ESR1 | |
| SCHEMBL25625593 | 0.78 | MAPT (0.50) | MEN1MAPTKMT2AALOX5ESR1 | |
| SCHEMBL5762395 | 0.77 | ESR1 (0.64) | MAPTIDO1ESR1ESR2 | |
| SCHEMBL28043207 | 0.75 | ESR1 (0.44) | MEN1MAPTKMT2AALOX5ESR1 | |
| SCHEMBL18121258 | 0.75 | MAPT (0.61) | MEN1MAPTKMT2AALOX5TYR | |
| SCHEMBL10721930 | 0.74 | ESR2 (0.46) | MEN1MAPTKMT2AALOX5NLRP3 | |
| SCHEMBL24037958 | 0.74 | HTR1D (0.39) | MEN1KMT2ANLRP3IDO1ESR1 | |
| SCHEMBL3235535 | 0.73 | ESR1 (0.55) | MAPTESR1ESR2TYRCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399692-A1 | NUCLEIC ACID DELIVERY SCAFFOLDS | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-12-14 | — | — | US | disclosed |
| US-20230399692-A1 | NUCLEIC ACID DELIVERY SCAFFOLDS | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-12-14 | — | — | US | disclosed |
| US-11840523-B2 | IRE1α inhibitors and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840523-B2 | IRE1α inhibitors and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-12-12 | — | — | US | disclosed |
| US-11795505-B2 | Nucleic acid delivery scaffolds | Singular Genomics Systems, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795505-B2 | Nucleic acid delivery scaffolds | Singular Genomics Systems, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230287204-A1 | OXIDIZED POLYISOBUTENE COMPOUNDS AND METHODS OF MAKING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-09-14 | — | — | US | disclosed |
| US-20230287491-A1 | NUCLEIC ACID DELIVERY SCAFFOLDS | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-09-14 | — | — | US | disclosed |
| US-20230287491-A1 | NUCLEIC ACID DELIVERY SCAFFOLDS | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-09-14 | — | — | US | disclosed |
| US-20230255934-A1 | NURR1 RECEPTOR MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-17 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230135758-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230135758-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230127630-A1 | IGF2BP2 INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-27 | — | — | US | disclosed |
| US-20230066830-A1 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER STEM CELLS | UNIV VIRGINIA COMMONWEALTH (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220396834-A1 | NANOARRAYS AND METHODS OF USE THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-12-15 | — | — | US | disclosed |
| US-20220154271-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-05-19 | — | — | US | disclosed |
| US-20220153720-A1 | IRE1ALPHA INHIBITORS AND USES THEREOF | UNIVERSITY OF WASHINGTON | 2022-05-19 | — | — | US | disclosed |
| US-11236387-B2 | Compositions and methods for nucleic acid sequencing | Singular Genomics Systems, Inc. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210040555-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING | FIRST-CITIZENS BANK & TRUST COMPANY | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | MEN1 3741/4885MAPT 4656/4885KMT2A 3044/4885 |
| US-11840523-B2 | IRE1α inhibitors and uses thereof | XBP1, ERN2, ERN1 | MEN1 4520/4885MAPT 2126/4885KMT2A 3648/4885 |
| US-20230066830-A1 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER STEM CELLS | SDCBP, BAX, MCL1 | MEN1 4230/4885MAPT 3422/4885KMT2A 4100/4885 |
| US-20230255934-A1 | NURR1 RECEPTOR MODULATORS AND USES THEREOF | NCOR1, NCOR2, NR4A2 | MEN1 4362/4885MAPT 3275/4885KMT2A 1209/4885 |
| US-20230135758-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | EEF1A1, EEF1B2, EEF1G | MEN1 3729/4885MAPT 2989/4885KMT2A 3519/4885 |
| US-20230127630-A1 | IGF2BP2 INHIBITORS AND USES THEREOF | IGF2BP2, IGF2BP1, IGFBP2 | MEN1 320/4885MAPT 4101/4885KMT2A 865/4885 |
| US-20220153720-A1 | IRE1ALPHA INHIBITORS AND USES THEREOF | XBP1, ERN2, ERN1 | MEN1 4489/4885MAPT 3333/4885KMT2A 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.